![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Safety, Tolerability, and Antiviral Activity of the siRNA VIR-2218 in Combination With the Investigational Neutralizing Monoclonal Antibody VIR-3434 For the Treatment of Chronic Hepatitis B Virus Infection: Preliminary Results From the Phase 2 MARCH Trial
|
|
|
AASLD 2022 Nov 4-8
![1110221](../images/111022/111022-18/1110221.gif)
![1110222](../images/111022/111022-18/1110222.gif)
![1110223](../images/111022/111022-18/1110223.gif)
![1110224](../images/111022/111022-18/1110224.gif)
![1110225](../images/111022/111022-18/1110225.gif)
![1110226](../images/111022/111022-18/1110226.gif)
![1110227](../images/111022/111022-18/1110227.gif)
![1110228](../images/111022/111022-18/1110228.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|